Drug Profile
VIR 1111
Alternative Names: VIR-1111Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Oregon Health & Science University; TomegaVax
- Developer Bill & Melinda Gates Foundation; Oregon Health & Science University; Vir Biotechnology
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in HIV-infections(Prevention) in USA (SC, Injection)
- 05 Dec 2022 Vir Biotechnology completes a phase-I clinical trial in HIV infections (Prevention) in USA (SC) (NCT04725877)
- 03 Nov 2022 Initial adverse events data from a phase I trial in HIV infections released by Vir Biotechnology